Stockscreener 앱 받기
1.03
5.50%
-0.06
시장 영업 전:
1.05
0.02
+1.94%
Allarity Therapeutics Inc 주식(ALLR)의 최신 뉴스
ALLR - Finviz
Form 8K Allarity Therapeutics Inc For: 17 September By Investing.com - Investing.com India
Allarity Therapeutics Is Maintained at Buy by Ascendiant Capital - Moomoo
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Ascendiant Capital maintains Buy rating on Allarity Therapeutics, $11 price target - TradingView
A cancer test to find patients likely to benefit gets a Japan patent - Stock Titan
Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development - Investing News Network
Form 8K Allarity Therapeutics Inc For: 14 September By Investing.com - Investing.com India
Allarity Therapeutics-backed SPAC files S-1 for $100M IPO; sponsor to hold ~25% - tradingview.com
Allarity Therapeutics files for $100 million SPAC offering By Investing.com - Investing.com Australia
Allarity Therapeutics Inc (ALLR) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement - Investing News Network
Allarity Therapeutics files for $100 million SPAC offering - Investing.com
Allarity Therapeutics Announces Strategic Capital Allocation For Filing Of Spac Registration Statement - TradingView
A former Novo Nordisk president will chair Allarity’s new acquisition company. The proposed offering is $100 million. - Stock Titan
Allarity Therapeutics Stock Price Forecast. Should You Buy ALLR? - StockInvest.us
Allarity Therapeutics Inc (ALLR) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Allarity Therapeutics Inc (ALLR) Key Financial Ratios – Valuation, Profitability & More - Value Research
Allarity Therapeutics Inc (ALLR) Peer Comparison – Compare with Others - Value Research
Allarity (ALLR) Financial Update: EPS Clears the Reported Estimate in the Latest Session; Trading Response: The Stock Closes Near Unchanged at the CloseEBITDA Estimate Trend - vinanet.vn
Allarity (ALLR) Earnings Update: The Available Earnings Metric Delivers a Beat; Price Move: Shares Move 5.93% Higher for the Current SessionEarnings Seasonality - vinanet.vn
Allarity Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Allarity Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign - Investing News Network
Allarity Therapeutics Q2 EPS of $(0.21) beats $(0.25) estimate - scanx.trade
Allarity Therapeutics reports Q2 results, cash position - Investing.com
Allarity Therapeutics, Inc. 2026: Revenue $0 Net income ($3.41M), EPS ($0.21) — 10-Q Summary - TradingView
Allarity Therapeutics reports Q2 results, cash position By Investing.com - Investing.com Canada
Allarity Therapeutics (ALLR) adds $20M debt, holds $26.9M cash in Q2 2026 - Stock Titan
Allarity Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready ... - Caledonian Record
Patent Gives Allarity’s Cancer-Drug Pairing Exclusivity Into 2042 - Stock Titan
Allarity Therapeutics Reports Second Quarter 2026 Results - GlobeNewswire
Allarity Therapeutics Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView
ALLR Q1 2026 Earnings: Narrower-than-Expected Loss of -$0.17 Highlights Cost DisciplineRevenue Warning Signal - dars.gov.et
Allarity Therapeutics (ALLR) Edges Higher: Biotech Stock Tests Key $1.42 Resistance After +1.5% MoveWyckoff Upthrust - careplusvn.com
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics - TMX Newsfile
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
Allarity Therapeutics (ALLR) Gains 2.48% as Stock Holds Above Key Support ZoneDividend ETF - dars.gov.et
Allarity Therapeutics Inc (ALLR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Allarity Therapeutics (ALLR) Slips 1.65% as Stock Tests Key Support LevelsHidden Order - careplusvn.com
Allarity Therapeutics, Inc. Revenue Breakdown – NASDAQ:ALLR - TradingView
Allarity Therapeutics Inc (ALLR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Allarity Therapeutics Inc (ALLR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Allarity Therapeutics Inc (ALLR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Allarity Therapeutics Inc (ALLR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ALLR|Allarity Therapeutics Inc|Price:1.190| - TradingKey
TradingKey - TradingKey
Allarity Therapeutics Inc (ALLR) Income Statement - TradingKey
ALLR Q1 2026 Earnings: EPS Beat by 24.24% as Pre-Revenue Biotech Faces Market SkepticismEarnings Risk Report - dars.gov.et
Allarity Therapeutics, Inc. (ALLR) stock price, news, quote and history - Yahoo Finance UK
Allarity Therapeutics, Inc. (ALLR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Allarity Therapeutics Inc (ALLR) News, Articles, Events & Latest Updates - Stocktwits
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year? - Yahoo Finance Australia
Update on One NASDAQ- Listed Pharmaceutical Stock– Allarity Therapeutics Inc - Kalkine
Allarity Therapeutics (ALLR) Edges Higher as Stock Tests Narrow Trading RangeTRIN Signal - dars.gov.et
Allarity Therapeutics Q1 2026 Earnings: Narrower Loss Surpasses Expectations as Biotech Focuses on Pipeline ExecutionEstimate Accuracy - dars.gov.et
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics - TMX Newsfile
Allarity Therapeutics (ALLR) Tests Support After 2.92% Decline – Key Levels Under ScrutinyLiquidity Sweep - dars.gov.et
3.06%
2.55%
자본화:
|
볼륨(24시간):